EGFR基因敏感突变晚期肺腺癌一线培美曲塞同药维持化疗疗效分析

目的:分析表皮生长因子受体(EGFR)基因敏感突变晚期肺腺癌患者一线培美曲塞维持化疗疗效。方法:对我院2012年6月始至今收治的伴有EGFR基因19或21外显子敏感突变的IIIb-IV期肺腺癌患者,一线接受培美曲塞联合顺铂后同药维持化疗的无进展生存时间(PFS)进行回顾性分析。结果:10例EGFR基因19和/或21外显子敏感突变的IIIb-IV期肺腺癌患者一线接受培美曲塞联合顺铂同药维持治疗，完全缓解(CR) 0例，部分缓解（PR）6例（60%），稳定（SD）4例（40%），疾病控制率（DCR）10例（100%），中位无进展生存时间（PFS）12.0个月（95%可信区间:7.60~16.30），1年生存率100%。主要毒副反应为骨髓抑制、恶心呕吐、疲劳乏力、神经毒性，安全可耐受。结论:EGFR基因敏感突变晚期肺腺癌患者一线培美曲塞维持化疗可取得较好疗效。

Effection of advanced lung adenocarcinoma with EGFR gene sensitive mutation who re-ceived pemetrexed first-line maintain chemotherapy

Objective:To analyze the effect of advanced lung adenocarcinoma with EGFR gene sensitive mutation who received first-line pemetrexed maintain chemotherapy. Methods:To retrospectively analyze the progress-free survival of advanced lung adenocarcinoma habor EGFR gene sensitive mutation who received first-line pemetrexed maintain chemotherapy since June 2012 in our oncology department. Results:There were 10 cases of stage Ⅲb -Ⅳ lung adenocarcinoma patients who habor EGFR gene sensitive mutation and they received first - line pemetrexed maintain chemotherapy. The patients who got complete response rate( CR),partial response( PR)and standard( SD) were 0,6 cases and 4 cases. The disease control rate(DCR),PFS,and 1 year survival rate of first-line pemetrexed maintain chemotherapy regimen were 100%,12. 0 month and 100% respectively. The main toxicity related to the first-line pemetrexed maintain chemotherapy were neutropenia,nausea,vomiting,neurotoxic and fatigue. Conclusion:It was efficacy of the first-line pemetrexed maintain chemotherapy in stage Ⅲb -Ⅳ lung adenocarcinoma who habor EGFR gene sensitive mutation.